Publications 2018

Agostini A, Brunetti M, Davidson B, Tropé CG, Eriksson AGZ, Heim S, Panagopoulos I, Micci F (2018)
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas
Sci Rep, 8 (1), 11069
DOI 10.1038/s41598-018-29332-7, PubMed 30038317

Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R (2018)
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
APMIS, 126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778

Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, Reich R (2018)
Expression and clinical role of long non-coding RNA in high-grade serous carcinoma
Gynecol Oncol, 148 (3), 559-566
DOI 10.1016/j.ygyno.2018.01.004, PubMed 29310950

Onallah H, Catane LJ, Tropé CG, Hetland Falkenthal TE, Reich R, Davidson B (2018)
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
Virchows Arch, 473 (4), 463-470
DOI 10.1007/s00428-018-2418-x, PubMed 30032361

Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161

Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149

Wang Z, Førsund MS, Trope CG, Nesland JM, Holm R, Slipicevic A (2018)
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
Cancer Med, 7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769

Publications 2017

Agostini A, Brunetti M, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F (2017)
Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression
Oncotarget, 8 (13), 21554-21560
DOI 10.18632/oncotarget.15795, PubMed 28423547

Brunetti M, Agostini A, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F (2017)
Recurrent fusion transcripts in squamous cell carcinomas of the vulva
Oncotarget, 8 (10), 16843-16850
DOI 10.18632/oncotarget.15167, PubMed 28186972

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432

Harel-Dassa K, Yedgar S, Tropé CG, Davidson B, Reich R (2017)
Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma
Hum Pathol, 62, 115-121
DOI 10.1016/j.humpath.2016.12.023, PubMed 28087476

Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187

Smebye ML, Agostini A, Johannessen B, Thorsen J, Davidson B, Tropé CG, Heim S, Skotheim RI, Micci F (2017)
Involvement of DPP9 in gene fusions in serous ovarian carcinoma
BMC Cancer, 17 (1), 642
DOI 10.1186/s12885-017-3625-6, PubMed 28893231

Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395

Publications 2016

Agostini A, Brunetti M, Davidson B, Trope CG, Heim S, Panagopoulos I, Micci F (2016)
Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva
Oncotarget, 7 (51), 85058-85062
DOI 10.18632/oncotarget.13187, PubMed 27835588

Agostini A, Panagopoulos I, Davidson B, Trope CG, Heim S, Micci F (2016)
A novel truncated form of HMGA2 in tumors of the ovaries
Oncol Lett, 12 (2), 1559-1563
DOI 10.3892/ol.2016.4805, PubMed 27446471

Broner EC, Tropé CG, Reich R, Davidson B (2016)
TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma
Hum Pathol, 60, 180-187
DOI 10.1016/j.humpath.2016.10.017, PubMed 27825812

Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
PLoS One, 11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508

Li Y, Huang R, Li X, Li X, Yu D, Zhang M, Wen J, Goscinski MA, Trope CG, Nesland JM, Suo Z (2016)
Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma
Am J Cancer Res, 6 (9), 2076-2087
PubMed 27725912

Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
Oncologist, 21 (6), 745-54
DOI 10.1634/theoncologist.2015-0239, PubMed 27009938

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471

Smebye ML, Haugom L, Davidson B, Trope CG, Heim S, Skotheim RI, Micci F (2016)
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes
Oncol Lett, 13 (1), 184-190
DOI 10.3892/ol.2016.5384, PubMed 28123539

Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555

Yu D, Holm R, Goscinski MA, Trope CG, Nesland JM, Suo Z (2016)
Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study
Am J Cancer Res, 6 (9), 2088-2097
PubMed 27725913

Publications 2015

Agostini A, Panagopoulos I, Andersen HK, Johannesen LE, Davidson B, Tropé CG, Heim S, Micci F (2015)
HMGA2 expression pattern and TERT mutations in tumors of the vulva
Oncol Rep, 33 (6), 2675-80
DOI 10.3892/or.2015.3882, PubMed 25823555

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2015)
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study
BMC Cancer, 15, 502
DOI 10.1186/s12885-015-1513-5, PubMed 26148881

Huang R, Wang J, Zhong Y, Liu Y, Stokke T, Trope CG, Nesland JM, Suo Z (2015)
Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties
Anticancer Res, 35 (7), 3743-53
PubMed 26124317

Katz B, Tropé CG, Reich R, Davidson B (2015)
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350

Li X, Huang R, Li RH, Trope CG, Nesland JM, Suo Z (2015)
Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients
Mol Clin Oncol, 4 (1), 18-22
DOI 10.3892/mco.2015.662, PubMed 26870350

Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R (2015)
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
PLoS One, 10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598

Publications 2014

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803

Davidson B, Tropé CG (2014)
Ovarian cancer: diagnostic, biological and prognostic aspects
Womens Health (Lond), 10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543

Davidson B, Tropé CG, Reich R (2014)
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546

Davidson B, Trope CG, Reich R (2014)
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303

Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194

Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323

Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
Eur J Cancer, 50 (11), 1942-50
DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045

Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085

Vaksman O, Tropé C, Davidson B, Reich R (2014)
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027

Wu Q, Shi H, Holm R, Li X, Trope C, Nesland JM, Suo Z (2014)
Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma
Anticancer Res, 34 (2), 859-65
PubMed 24511023

Publications 2013

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953

Dhakal HP, Nesland JM, Førsund M, Trope CG, Holm R (2013)
Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact
BMC Cancer, 13, 506
DOI 10.1186/1471-2407-13-506, PubMed 24165149

Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S (2013)
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer
Int J Gynecol Cancer, 23 (5), 839-45
DOI 10.1097/IGC.0b013e3182907109, PubMed 23694981

Holm R, Førsund M, Nguyen MT, Nesland JM, Trope CG (2013)
Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma
PLoS One, 8 (4), e61273
DOI 10.1371/journal.pone.0061273, PubMed 23580324

Huang R, Ma Y, Holm R, Trope CG, Nesland JM, Suo Z (2013)
Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations
PLoS One, 8 (12), e83238
DOI 10.1371/journal.pone.0083238, PubMed 24386165

Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R (2013)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
BMC Cancer, 13, 288
DOI 10.1186/1471-2407-13-288, PubMed 23767999

Micci F, Panagopoulos I, Haugom L, Dahlback HS, Pretorius ME, Davidson B, Abeler VM, Tropé CG, Danielsen HE, Heim S (2013)
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva
Genes Chromosomes Cancer, 52 (6), 551-63
DOI 10.1002/gcc.22053, PubMed 23404381

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671

Vaksman O, Davidson B, Tropé C, Reich R (2013)
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum Pathol, 44 (12), 2677-83
DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004

Publications 2012

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560

Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C (2012)
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104

Davidson B, Tropé CG, Reich R (2012)
Epithelial-mesenchymal transition in ovarian carcinoma
Front Oncol, 2, 33
DOI 10.3389/fonc.2012.00033, PubMed 22655269

Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG (2012)
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J (2012)
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
Ann Surg Oncol, 20 (4), 1348-54
DOI 10.1245/s10434-012-2673-z, PubMed 23054114

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921

Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z (2012)
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
DOI 10.1186/1471-2407-12-201, PubMed 22642602

Pradhan M, Davidson B, Abeler VM, Danielsen HE, Tropé CG, Kristensen GB, Risberg BÅ (2012)
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999

Tropé CG, Abeler VM, Kristensen GB (2012)
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
DOI 10.3109/0284186X.2012.689111, PubMed 22793037

Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012)
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201

Tropé CG, Kaern J, Davidson B (2012)
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906

Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B (2012)
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351

Weiss I, Trope CG, Reich R, Davidson B (2012)
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
Int J Mol Sci, 13 (10), 12925-38
DOI 10.3390/ijms131012925, PubMed 23202930

Publications 2011

Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B (2011)
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668

Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B (2011)
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111

Davidson B, Holth A, Moripen L, Trope' CG, Shih IeM (2011)
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424

Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B (2011)
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542

Elstrand MB, Stavnes HT, Tropé CG, Davidson B (2011)
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883

Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM (2011)
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
Mol Pharm, 8 (6), 2080-8
DOI 10.1021/mp200240a, PubMed 21761824

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408

Oksefjell H, Sandstad B, Tropé C (2011)
The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
Eur J Gynaecol Oncol, 32 (4), 369-76
PubMed 21941955

Paulsen T, Kærn J, Tropé C (2011)
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701

Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2011)
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-1184
DOI 10.1093/annonc/mdr368, PubMed 21965471

Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P (2011)
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Ann Surg Oncol, 19 (2), 597-604
DOI 10.1245/s10434-011-1873-2, PubMed 21732142

Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115

Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A (2011)
Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
J Clin Oncol, 29 (31), 4076-8
DOI 10.1200/JCO.2011.36.9785, PubMed 21931032

Wang Z, Nesland JM, Suo Z, Trope CG, Holm R (2011)
The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors
PLoS One, 6 (9), e24843
DOI 10.1371/journal.pone.0024843, PubMed 21935479

Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS (2011)
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Br J Cancer, 105 (7), 890-6
DOI 10.1038/bjc.2011.328, PubMed 21878937

Publications 2010

Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC (2010)
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
Int J Gynecol Cancer, 20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029

Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B (2010)
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512

Davidson B, Reich R, Trope CG, Wang TL, Shih IeM (2010)
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol Histopathol, 25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439

Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R (2010)
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin Exp Metastasis, 27 (3), 161-72
DOI 10.1007/s10585-010-9315-2, PubMed 20213325

Micci F, Haugom L, Ahlquist T, Andersen HK, Abeler VM, Davidson B, Trope CG, Lothe RA, Heim S (2010)
Genomic aberrations in borderline ovarian tumors
J Transl Med, 8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781

Micci F, Skotheim RI, Haugom L, Weimer J, Eibak AM, Abeler VM, Trope CG, Arnold N, Lothe RA, Heim S (2010)
Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
Genes Chromosomes Cancer, 49 (11), 1046-53
DOI 10.1002/gcc.20813, PubMed 20725991

Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A (2010)
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665

Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL (2010)
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
Am J Pathol, 177 (3), 1087-94
DOI 10.2353/ajpath.2010.100316, PubMed 20671266

Pradhan M, Abeler VM, Davidson B, Kildal W, Nybøen A, Tropé CG, Risberg B, Danielsen HE (2010)
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
Int J Gynecol Pathol, 29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853

Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH (2010)
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
BMC Cancer, 10, 493
DOI 10.1186/1471-2407-10-493, PubMed 20843305

Tropé CG (2010)
Management of cervical carcinoma stage IV: comment.
CME Journal of Gynecologic Oncology, 15 (1), 69-71
PublikaID 105

Tropé CG, Kristensen GB (2010)
Surgery in treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 33-39
PublikaID 104

Tropé CG, Kristensen GB (2010)
The treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 72-90
PublikaID 106

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med, 363 (10), 943-53
DOI 10.1056/NEJMoa0908806, PubMed 20818904

Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813

Yuan Y, Leszczynska M, Konstantinovsky S, Tropé CG, Reich R, Davidson B (2010)
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
Diagn Cytopathol, 39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893

Publications 2009

Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R (2009)
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
Hum Pathol, 40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507

Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B (2009)
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
Am J Clin Pathol, 132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B (2009)
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
Int J Gynecol Pathol, 28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938

Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, Flørenes VA, Davidson B (2009)
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506

Knopp S, Tropè C, Nesland JM, Holm R (2009)
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
J Clin Pathol, 62 (3), 212-8
DOI 10.1136/jcp.2008.057240, PubMed 19251952

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2009)
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
BMC Cancer, 9, 2
DOI 10.1186/1471-2407-9-2, PubMed 19121203

Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A (2009)
Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
Int J Gynecol Cancer, 19 (4), 634-40
DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562

Micci F, Haugom L, Ahlquist T, Abeler VM, Trope CG, Lothe RA, Heim S (2009)
Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution
J Oncol, 2010, 646340
DOI 10.1155/2010/646340, PubMed 19759843

Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, Abeler VM, Silins I, Lothe RA, Trope CG, Arnold N, Heim S (2009)
Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map
Genes Chromosomes Cancer, 48 (2), 184-93
DOI 10.1002/gcc.20628, PubMed 18973136

Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009)
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
Int J Gynecol Cancer, 19 (6), 1029-36
DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364

Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B (2009)
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
Virchows Arch, 454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773

Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396

Tropé C, Iversen OE (2009)
[From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
DOI 10.4045/tidsskr.09.0067, PubMed 19337352

Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IeM, Low PS, Trope' CG, Davidson B (2009)
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
Hum Pathol, 40 (10), 1453-60
DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358

Publications 2008

Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B (2008)
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388

Kleinberg L, Holth A, Trope CG, Reich R, Davidson B (2008)
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Hum Pathol, 39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941

Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson B, Risberg B (2008)
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
Diagn Cytopathol, 36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760

Knopp S, Nesland JM, Tropé C (2008)
SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
Surg Oncol, 17 (3), 219-25
DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194

Micci F, Haugom L, Abeler VM, Tropé CG, Danielsen HE, Heim S (2008)
Consistent numerical chromosome aberrations in thecofibromas of the ovary
Virchows Arch, 452 (3), 269-76
DOI 10.1007/s00428-007-0561-x, PubMed 18188592

Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A (2008)
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
Eur J Cancer, 45 (1), 82-9
DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092

Oksefjell H, Sandstad B, Tropé C (2008)
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
Ann Oncol, 20 (2), 286-93
DOI 10.1093/annonc/mdn591, PubMed 18725390

Oksefjell H, Sandstad B, Tropé C (2008)
Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
Eur J Gynaecol Oncol, 29 (6), 583-9
PubMed 19115683

Wang Z, Tropè CG, Suo Z, Trøen G, Yang G, Nesland JM, Holm R (2008)
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
BMC Cancer, 8, 308
DOI 10.1186/1471-2407-8-308, PubMed 18950492

Publications 2007

Davidson B, Berner A, Trope' CG, Wang TL, Shih IM (2007)
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
Hum Pathol, 38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728

Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260

Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2007)
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 61 (1), 59-63
DOI 10.1136/jcp.2006.045864, PubMed 17468294

Kleinberg L, Flørenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B (2007)
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759

Liavaag AH, Dørum A, Bjøro T, Oksefjell H, Fosså SD, Tropé C, Dahl AA (2007)
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
Gynecol Oncol, 108 (2), 348-54
DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925

Liavaag AH, Dørum A, Fosså SD, Tropé C, Dahl AA (2007)
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
J Clin Oncol, 25 (15), 2049-56
DOI 10.1200/JCO.2006.09.1769, PubMed 17513809

Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG (2007)
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
Cancer, 109 (4), 645-9
DOI 10.1002/cncr.22467, PubMed 17238177

Oksefjell H, Sandstad B, Tropé C (2007)
Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
Eur J Gynaecol Oncol, 28 (4), 256-62
PubMed 17713088

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213

Tropé C, Kaern J (2007)
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
J Clin Oncol, 25 (20), 2909-20
DOI 10.1200/JCO.2007.11.1013, PubMed 17617522

Wu Q, Lind GE, Aasheim HC, Micci F, Silins I, Tropé CG, Nesland JM, Lothe RA, Suo Z (2007)
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
Epigenetics, 2 (4), 237-43
DOI 10.4161/epi.2.4.5406, PubMed 18281782

Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, Nesland JM, Suo Z, Lind GE (2007)
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
Mol Cancer, 6, 45
DOI 10.1186/1476-4598-6-45, PubMed 17623056

Zhang MZ, Qiao YH, Nesland JM, Trope C, Kennedy A, Chen WT, Suo ZH (2007)
Expression of seprase in effusions from patients with epithelial ovarian carcinoma
Chin Med J (Engl), 120 (8), 663-8
PubMed 17517181

Publications 2006

Davidson B, Espina V, Steinberg SM, Flørenes VA, Liotta LA, Kristensen GB, Tropé CG, Berner A, Kohn EC (2006)
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090

Davidson B, Shafat I, Risberg B, Ilan N, Trope' CG, Vlodavsky I, Reich R (2006)
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
Gynecol Oncol, 104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350

Davidson B, Trope' CG, Wang TL, Shih IeM (2006)
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
Gynecol Oncol, 103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205

Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am J Clin Pathol, 125 (3), 451-8
DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351

Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006)
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
Virchows Arch, 449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R (2006)
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
Gynecol Oncol, 103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2006)
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 60 (10), 1086-91
DOI 10.1136/jcp.2006.041194, PubMed 17158642

Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM (2006)
Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
Histopathology, 49 (3), 311-2
DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980

Knopp S, Nesland JM, Tropé C, Holm R (2006)
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
Am J Clin Pathol, 126 (2), 266-76
DOI 10.1309/e9e8y9wg5qe3lk29, PubMed 16891203

Oksefjell H, Sandstad B, Trope C (2006)
Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
Eur J Gynaecol Oncol, 27 (3), 209-14
PubMed 16800244

Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277

Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561

Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BA (2006)
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
Mod Pathol, 19 (9), 1227-35
DOI 10.1038/modpathol.3800641, PubMed 16729014

Sert B, Abeler VM, Dørum A, Trope CG (2006)
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
Eur J Gynaecol Oncol, 27 (5), 513-8
PubMed 17139990

Tropé C, Kaern J (2006)
Primary surgery for ovarian cancer
Eur J Surg Oncol, 32 (8), 844-52
DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797

Publications 2005

Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM (2005)
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
Gynecol Oncol, 96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578

Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F (2005)
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am J Clin Pathol, 123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231

Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005)
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
Cancer, 103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334

Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005)
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177

Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R (2005)
Cyclins D1, D3, E, and A in vulvar carcinoma patients
Gynecol Oncol, 97 (3), 733-9
DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358

Knopp S, Holm R, Tropé C, Nesland JM (2005)
Occult lymph node metastases in early stage vulvar carcinoma patients
Gynecol Oncol, 99 (2), 383-7
DOI 10.1016/j.ygyno.2005.06.023, PubMed 16051338

Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, Nordal R, Norheim OF, Onsrud M, Tretli S, Tropé C (2005)
[Primary treatment of ovarian cancer]
Tidsskr Nor Laegeforen, 125 (3), 278-81
PubMed 15702146

Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005)
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702

Salvesen HB, Iversen OE, Tropé C (2005)
[Molecular diagnostic techniques in gynaecologic cancer]
Tidsskr Nor Laegeforen, 125 (22), 3120-3
PubMed 16299569

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759

Shih IeM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL (2005)
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Proc Natl Acad Sci U S A, 102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393

Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope' CG, Kohn EC, Davidson B (2005)
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
Cancer, 103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177

Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2005)
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317

Publications 2004

Bjørge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, Langseth H, Nustad K, Tropé CG, Dørum A (2004)
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
Br J Cancer, 91 (10), 1829-34
DOI 10.1038/sj.bjc.6602199, PubMed 15477862

Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC (2004)
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056

Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R (2004)
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
Gynecol Oncol, 93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972

Kildal W, Kaern J, Kraggerud SM, Abeler VM, Sudbø J, Tropè CG, Lothe RA, Danielsen HE (2004)
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
Cancer Genet Cytogenet, 155 (1), 25-32
DOI 10.1016/j.cancergencyto.2004.02.010, PubMed 15527899

Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R (2004)
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Gynecol Oncol, 95 (1), 37-45
DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108

Kristensen G, Tropé C (2004)
Endometrial cancer: the management of high-risk disease
Curr Oncol Rep, 6 (6), 471-5
DOI 10.1007/s11912-004-0078-2, PubMed 15485617

Suo Z, Karbovo E, Trope CG, Metodiev K, Nesland JM (2004)
Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study
Ultrastruct Pathol, 28 (3), 141-7
DOI 10.1080/01913120490475716, PubMed 15471427

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786

Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004)
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123

Publications 2003

Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Trope CG, Schaefer E, Reich R (2003)
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793

Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Trope' CG, Risberg B, Kopolovic J (2003)
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
Gynecol Oncol, 90 (2), 248-57
DOI 10.1016/s0090-8258(03)00321-4, PubMed 12893184

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393

Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
A systematic overview of radiation therapy effects in cervical cancer (cervix uteri)
Acta Oncol, 42 (5-6), 546-56
DOI 10.1080/02841860310014660, PubMed 14596512

Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
A systematic overview of radiation therapy effects in uterine cancer (corpus uteri)
Acta Oncol, 42 (5-6), 557-61
DOI 10.1080/02841860310014417, PubMed 14596513

Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E (2003)
A systematic overview of radiation therapy effects in ovarian cancer
Acta Oncol, 42 (5-6), 562-6
DOI 10.1080/02841860310014426, PubMed 14596514

Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R (2003)
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
Gynecol Oncol, 91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677

Kildal W, Kraggerud SM, Abeler VM, Heim S, Tropé CG, Kristensen GB, Risberg B, Lothe RA, Danielsen HE (2003)
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
Hum Pathol, 34 (9), 946-9
DOI 10.1016/s0046-8177(03)00345-9, PubMed 14562293

Kohn EC, Fidler IJ, Fishman D, Jaffe R, Liotta LA, Van Trappen P, Mills GB, Trope C (2003)
Discussion: Metastasis and angiogenesis in epithelial ovarian cancer
Gynecol. Oncol., 88 (1), S37-S42
DOI 10.1006/gyno.2002.6681

Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE (2003)
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
DOI 10.1093/annonc/mdg403, PubMed 14504048

Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Lancet, 361 (9375), 2099-106
DOI 10.1016/s0140-6736(03)13718-x, PubMed 12826431

Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B et al. (2003)
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 144-8
DOI 10.1111/j.1525-1438.2003.13357.x, PubMed 14656271

Thorstensen L, Holm R, Lothe RA, Tropé C, Carvalho B, Sobrinho-Simoes M, Seruca R (2003)
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas
Gastroenterology, 124 (1), 270-1
DOI 10.1053/gast.2003.50034, PubMed 12512062

Tropé C, Kaern J, Saeter G, Gore M (2003)
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184

van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB (2003)
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
Gynecol Oncol, 89 (1), 140-7
DOI 10.1016/s0090-8258(03)00010-6, PubMed 12694668

Publications 2002

Bjørge T, Abeler VM, Sundfør K, Tropé CG, Kaern J (2002)
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
Gynecol Oncol, 87 (1), 71-6
DOI 10.1006/gyno.2002.6801, PubMed 12468345

Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R (2002)
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219

Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I (2002)
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077

Kaern J, Baekelandt M, Tropé CG (2002)
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
Eur J Gynaecol Oncol, 23 (5), 383-9
PubMed 12440808

Karbova E, Davidson B, Metodiev K, Tropé CG, Nesland JM (2002)
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
Int J Surg Pathol, 10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570

Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø (2002)
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer, 94 (3), 707-12
DOI 10.1002/cncr.10250, PubMed 11857303

Scheistrøen M, Nesland JM, Tropé C (2002)
Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
Eur J Gynaecol Oncol, 23 (2), 93-103
PubMed 12013120

Tropé C (2002)
[Mass screening against endometrial cancer?]
Tidsskr Nor Laegeforen, 122 (18), 1767
PubMed 12362684

Tropé C (2002)
[Laparoscopic surgery in endometrial carcinoma]
Tidsskr Nor Laegeforen, 122 (25), 2429
PubMed 12448107

Publications 2001

Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB (2001)
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
J Clin Oncol, 19 (12), 2983-93
DOI 10.1200/JCO.2001.19.12.2983, PubMed 11408493

Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R (2001)
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899

Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R (2001)
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863

Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J, Nesland JM (2001)
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382

Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G, Flørenes VA (2001)
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079

Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Tropé CG, Kristensen GB, Bryne M, Reich R (2001)
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
Am J Surg Pathol, 25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538

Makar AP, Scheistroen M, van den Weyngaert D, Tropé CG (2001)
Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature
Int J Gynecol Cancer, 11 (4), 255-62
DOI 10.1046/j.1525-1438.2001.011004255.x, PubMed 11520362

Makar AP, Tropé C (2001)
Fertility preservation in gynecologic cancer
Acta Obstet Gynecol Scand, 80 (9), 794-802
DOI 10.1034/j.1600-0412.2001.080009794.x, PubMed 11531628

Tropé C, Kristensen G, Kisic J, Kaern J (2001)
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778

Tropé C, Kristensen GB, Abeler VM (2001)
Clear-cell and papillary serous cancer: treatment options
Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
DOI 10.1053/beog.2000.0187, PubMed 11476564

Tropé C, Scheistrøen M, Makar AP (2001)
[Fertility preservation in gynecologic cancer]
Tidsskr Nor Laegeforen, 121 (10), 1234-9
PubMed 11402751

Tropé C, Scheistrøen M, Aas M, Abeler V, Lie K, Makar A (2001)
[Surgery and sentinel node examination in early vulvar cancer]
Tidsskr Nor Laegeforen, 121 (23), 2723-7
PubMed 11699381

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG (2001)
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
Lancet, 357 (9251), 176-82
DOI 10.1016/S0140-6736(00)03590-X, PubMed 11213094

Publications 2000

Abeler VM, Tropé CG (2000)
[Early stage ovarian carcinoma--diagnosis and treatment]
Tidsskr Nor Laegeforen, 120 (4), 476-8
PubMed 10833940

Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490

Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Tropé CG, Abeler VM (2000)
Carcinoma of the fallopian tube
Cancer, 89 (10), 2076-84
PubMed 11066048

Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT et al. (2000)
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]
Gynecol Obstet Fertil, 28 (7-8), 576-83
PubMed 10996969

Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000)
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
Clin Exp Metastasis, 18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996

Bjørge T, Dørum A, Tropé CG (2000)
[Screening for ovarian cancer]
Tidsskr Nor Laegeforen, 120 (12), 1444-8
PubMed 10851943

Bye A, Tropé C, Loge JH, Hjermstad M, Kaasa S (2000)
Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment
Acta Oncol, 39 (2), 173-80
DOI 10.1080/028418600430734, PubMed 10859007

Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863

Davidson B, Berner A, Nesland JM, Risberg B, Kristensen GB, Tropé CG, Bryne M (2000)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
DOI 10.1053/hupa.2000.9776, PubMed 11014575

Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Tropé CG, Peltomäki P, Lothe RA (2000)
DNA copy number changes in malignant ovarian germ cell tumors
Cancer Res, 60 (11), 3025-30
PubMed 10850452

Lyng H, Sundfør K, Tropé C, Rofstad EK (2000)
Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
Clin Cancer Res, 6 (3), 1104-12
PubMed 10741740

Makar AP, Kisic J, Tropé CG (2000)
Controversies in surgical management of advanced ovarian cancer (stage III-IV)
Eur J Gynaecol Oncol, 21 (5), 449-60
PubMed 11198031

Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
DOI 10.1006/gyno.1999.5699, PubMed 10684705

Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B et al. (2000)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
J Natl Cancer Inst, 92 (9), 699-708
DOI 10.1093/jnci/92.9.699, PubMed 10793106

Rofstad EK, Sundfør K, Lyng H, Tropé CG (2000)
Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
Br J Cancer, 83 (3), 354-9
DOI 10.1054/bjoc.2000.1266, PubMed 10917551

Sundfør K, Lyng H, Tropé CG, Rofstad EK (2000)
Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization
Radiother Oncol, 54 (2), 101-7
DOI 10.1016/s0167-8140(99)00175-9, PubMed 10699471

Tropé C (2000)
[Ovarian cancer screening of high risk groups]
Tidsskr Nor Laegeforen, 120 (18), 2191
PubMed 11006746

Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I (2000)
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
DOI 10.1023/a:1008399414923, PubMed 10811493

Tropé C, Marth C, Kaern J (2000)
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer, 36 Suppl 4, S59-61
DOI 10.1016/s0959-8049(00)00228-8, PubMed 11056321

Tropé C, Paulsen T, Baekelandt M, Makar A (2000)
[Controversies in surgical treatment of advanced ovarian cancer]
Tidsskr Nor Laegeforen, 120 (7), 824-30
PubMed 10806907

Tropé CG, Abeler V, Baekelandt M, Kaern J (2000)
[DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]
Tidsskr Nor Laegeforen, 120 (1), 43-9
PubMed 10815478

Tropé CG, Baekelandt M, Bjørge T, Abeler V, Kaern J (2000)
[Borderline tumors of the ovary]
Tidsskr Nor Laegeforen, 120 (23), 2764-70
PubMed 11107921

Tropé CG, Kisic J, Vergote I (2000)
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide
Eur J Gynaecol Oncol, 21 (3), 255-9
PubMed 10949388

Tropé CG, Kristensen G, Makar A (2000)
Surgery for borderline tumor of the ovary
Semin Surg Oncol, 19 (1), 69-75
DOI 10.1002/1098-2388(200007/08)19:1<69::aid-ssu11>3.0.co;2-e, PubMed 10883027

Publications 1999

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study
Clin Cancer Res, 5 (10), 2848-53
PubMed 10537352

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer
Ann Oncol, 10 (11), 1335-41
DOI 10.1023/a:1008352502465, PubMed 10631462

Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R (1999)
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer
J Clin Oncol, 17 (7), 2061
DOI 10.1200/JCO.1999.17.7.2061, PubMed 10561259

Baekelandt M, Kristensen GB, Tropé CG, Nesland JM, Holm R (1999)
Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer
Anticancer Res, 19 (5C), 4469-74
PubMed 10650794

Berek JS, Tropé C, Vergote I (1999)
Surgery during chemotherapy and at relapse of ovarian cancer
Ann Oncol, 10 Suppl 1, 3-7
DOI 10.1023/a:1008338830718, PubMed 10219446

Bjørge T, Tropé CG, Engeland A (1999)
[Screening for cancer]
Tidsskr Nor Laegeforen, 119 (8), 1129-36
PubMed 10228417

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P (1999)
Prospectively detected cancer in familial breast/ovarian cancer screening
Acta Obstet Gynecol Scand, 78 (10), 906-11
DOI 10.1034/j.1600-0412.1999.781013.x, PubMed 10577622

Dørum A, Hovig E, Tropé C, Inganas M, Møller P (1999)
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA
Eur J Cancer, 35 (5), 779-81
DOI 10.1016/s0959-8049(99)00050-7, PubMed 10505039

Marth C, Sundfor K, Kaern J, Tropé C (1999)
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix
Acta Oncol, 38 (4), 517-20
DOI 10.1080/028418699432077, PubMed 10418721

Ozols RF, Gore M, Tropé C, Grenman S (1999)
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
Ann Oncol, 10 Suppl 1, 59-64
DOI 10.1023/a:1008363519331, PubMed 10219455

Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye SB, Tropé C, Swenerton K, Harper P, Vermorken JB (1999)
Intergroup collaboration in ovarian cancer: a giant step forward
Ann Oncol, 10 Suppl 1, 83-6
DOI 10.1023/a:1008371821148, PubMed 10219459

Scheistrøen M, Tropé C, Pettersen EO, Nesland JM (1999)
p53 protein expression in squamous cell carcinoma of the vulva
Cancer, 85 (5), 1133-8
DOI 10.1002/(SICI)1097-0142(19990301)85:5<1133::AID-CNCR17>3.0.CO;2-T, PubMed 10091798

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R (1999)
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
J Pathol, 187 (5), 556-62
DOI 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y, PubMed 10398121

Sundfør K, Trope C, Suo Z, Bergsjø P (1999)
Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial
Radiother Oncol, 50 (2), 157-65
DOI 10.1016/s0167-8140(98)00142-x, PubMed 10368039

Tropé CG, Marth C, Scheistrøen M, Abeler VM (1999)
[Endometrial hyperplasia--diagnosis and treatment]
Tidsskr Nor Laegeforen, 119 (14), 2030-4
PubMed 10394278

Publications 1998

Bjørge T, Engeland A, Hansen S, Tropé CG (1998)
Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
Int J Cancer, 75 (5), 663-70
DOI 10.1002/(sici)1097-0215(19980302)75:5<663::aid-ijc1>3.0.co;2-x, PubMed 9495231

Bjørge T, Engeland A, Hansen S, Tropé CG (1998)
[Ovarian cancer and borderline tumors]
Tidsskr Nor Laegeforen, 118 (16), 2471-5
PubMed 9667122

Bjørge T, Engeland A, Sundfør K, Tropé CG (1998)
Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital
Acta Obstet Gynecol Scand, 77 (7), 777-81
DOI 10.1080/j.1600-0412.1998.770714.x, PubMed 9740528

Hofstra LS, Kristensen GB, Willemse PH, Vindevoghel A, Meden H, Lahousen M, Oberling F, Sorbe B, Crump M, Sklenar I, Sluiter WJ, Kiese B, Trope CG, de Vries EG (1998)
Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma
J Clin Oncol, 16 (10), 3335-44
DOI 10.1200/JCO.1998.16.10.3335, PubMed 9779710

Marth C, Tropé C, Vergote IB, Kristensen GB (1998)
Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer
Eur J Cancer, 34 (8), 1175-80
DOI 10.1016/s0959-8049(97)10171-x, PubMed 9849475

Moller P, Maehle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jorgensen OG, Helgerud P, Qvist H, Bjorndal H, Kullmann G, Bohler P, Nysted A, Soreide JA, Varhaug JE, Aas T, Fjosne HE, Hagen A, Due J, Karesen R, Formoe E, Malme PA, Stedjeberg JO, Svenningsen SS et al. (1998)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
Breast, 7 (1), 55-59
DOI 10.1016/S0960-9776(98)90053-4

Nordal RR, Kristensen GB, Stenwig AE, Tropé CG, Nesland JM (1998)
Immunohistochemical analysis of p53 protein in uterine sarcomas
Gynecol Oncol, 70 (1), 45-8
DOI 10.1006/gyno.1998.5034, PubMed 9698472

Paulsen T, Kaern J, Tropé C (1998)
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Eur J Gynaecol Oncol, 19 (6), 524-8
PubMed 10215433

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL (1998)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
DOI 10.1038/bjc.1998.502, PubMed 9703286

Tropé C (1998)
Prognostic factors in ovarian cancer
Cancer Treat Res, 95, 287-352
DOI 10.1007/978-1-4615-5447-9_11, PubMed 9619290

Tropé C, Hogberg T, Kaern J, Bertelsen K, Bjorkholm E, Boman K, Himmelmann A, Horvath G, Jacobsen A, Kuoppola T, Vartianen J, Lund B, Onsrud M, Puistola U, Salmi T, Scheistroen M, Sandvei R, Simonsen E, Sorbe B, Tholander B, Westberg R (1998)
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience
Ann Oncol, 9 (12), 1301-7
DOI 10.1023/a:1008400324892, PubMed 9932160

Tropé C, Kaern J (1998)
Management of borderline tumors of the ovary: state of the art
Semin Oncol, 25 (3), 372-80
PubMed 9633850

Publications 1997

Bjørge T, Engeland A, Hansen S, Tropé CG (1997)
Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993
Int J Cancer, 71 (5), 780-6
DOI 10.1002/(sici)1097-0215(19970529)71:5<780::aid-ijc15>3.0.co;2-c, PubMed 9180146

Bjørge T, Tropé C (1997)
[Hormone replacement therapy and cancer]
Tidsskr Nor Laegeforen, 117 (15), 2201-7
PubMed 9235712

Blomlie V, Rofstad EK, Tropé C, Lien HH (1997)
Critical soft tissues of the female pelvis: serial MR imaging before, during, and after radiation therapy
Radiology, 203 (2), 391-7
DOI 10.1148/radiology.203.2.9114093, PubMed 9114093

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P (1997)
The problem of skipped generation and subclinical disease in familial breast-ovarian cancer
Acta Obstet Gynecol Scand, 76 (2), 166-8
DOI 10.3109/00016349709050074, PubMed 9049291

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ (1997)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
Eur J Cancer, 33 (14), 2390-2
DOI 10.1016/s0959-8049(97)00328-6, PubMed 9616287

Kristensen GB, Tropé C (1997)
Epithelial ovarian carcinoma
Lancet, 349 (9045), 113-7
DOI 10.1016/S0140-6736(96)06071-0, PubMed 8996432

Marth C, Sorheim N, Kaern J, Trope C (1997)
Tamoxifen in the treatment of recurrent ovarian carcinoma
Int. J. Gynecol. Cancer, 7 (4), 256-261
DOI 10.1046/j.1525-1438.1997.00463.x

Marth C, Widschwendter M, Kaern J, Jørgensen NP, Windbichler G, Zeimet AG, Tropé C, Daxenbichler G (1997)
Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
Br J Cancer, 76 (10), 1328-32
DOI 10.1038/bjc.1997.556, PubMed 9374379

Marth C, Zeimet AG, Widschwendter M, Ludescher C, Kaern J, Tropé C, Gastl G, Daxenbichler G, Dapunt O (1997)
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells
Cancer Res, 57 (17), 3818-22
PubMed 9288793

Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Trope CG (1997)
An evaluation of prognostic factors in uterine carcinosarcoma
Gynecol Oncol, 67 (3), 316-21
DOI 10.1006/gyno.1997.4875, PubMed 9441781

Scheistrøen M, Tropé C, Kaern J, Pettersen EO, Alfsen GC, Nesland JM (1997)
DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva
Gynecol Oncol, 64 (1), 88-92
DOI 10.1006/gyno.1996.4517, PubMed 8995553

Skomedal H, Kristensen GB, Abeler VM, Børresen-Dale AL, Tropé C, Holm R (1997)
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas
J Pathol, 181 (2), 158-65
DOI 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8, PubMed 9120719

Sundfør K, Lyng H, Kongsgård UL, Tropé C, Rofstad EK (1997)
Polarographic measurement of pO2 in cervix carcinoma
Gynecol Oncol, 64 (2), 230-6
DOI 10.1006/gyno.1996.4571, PubMed 9038268

Tropé C, Kaern J, Kristensen G, Rosenberg P, Sorbe B (1997)
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer
Ann Oncol, 8 (8), 803-6
DOI 10.1023/a:1008230909599, PubMed 9332691

Tropé C, Kristensen G (1997)
Current status of chemotherapy in gynecologic cancer
Semin Oncol, 24 (5 Suppl 15), S15-1-S15-22
PubMed 9346216

Trope C, Kristensen G (1997)
Current status of chemotherapy in gynecologic cancer
Semin. Oncol., 24 (5 15), 1-22

Publications 1996

Abeler VM, Vergote IB, Kjørstad KE, Tropé CG (1996)
Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern
Cancer, 78 (8), 1740-7
DOI 10.1002/(sici)1097-0142(19961015)78:8<1740::aid-cncr14>3.0.co;2-y, PubMed 8859187

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P (1996)
Early detection of familial ovarian cancer
Eur J Cancer, 32A (10), 1645-51
DOI 10.1016/0959-8049(96)00137-2, PubMed 8983269

Kaern J, Tropé C, Sundfoer K, Kristensen GB (1996)
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Gynecol Oncol, 60 (3), 387-92
DOI 10.1006/gyno.1996.0059, PubMed 8774643

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study
Gynecol Oncol, 61 (3), 378-83
DOI 10.1006/gyno.1996.0160, PubMed 8641619

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study
Cancer, 78 (3), 433-40
DOI 10.1002/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K, PubMed 8697388

Kristensen GB, Karlsen F, Jenkins A, Kaern J, Abeler VM, Tropé CG (1996)
Human papilloma virus has no prognostic significance in cervical carcinoma
Eur J Cancer, 32A (8), 1349-53
DOI 10.1016/0959-8049(96)00089-5, PubMed 8869098

Lyng H, Sundfør K, Tropé C, Rofstad EK (1996)
Oxygen tension and vascular density in human cervix carcinoma
Br J Cancer, 74 (10), 1559-63
DOI 10.1038/bjc.1996.589, PubMed 8932335

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S (1996)
Inherited breast carcinoma--prospective findings in 1,194 women at risk
Acta Oncol, 35 Suppl 8, 7-11
DOI 10.3109/02841869609098515, PubMed 9073043

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1996)
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma
Gynecol Oncol, 62 (2), 254-9
DOI 10.1006/gyno.1996.0224, PubMed 8751558

Scheistrøen M, Tropé C, Kaern J, Abeler VM, Pettersen EO, Kristensen GB (1996)
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment
Gynecol Oncol, 61 (2), 253-8
DOI 10.1006/gyno.1996.0135, PubMed 8626143

Sundfør K, Tropé CG, Högberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg R (1996)
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A
Cancer, 77 (11), 2371-8
DOI 10.1002/(SICI)1097-0142(19960601)77:11<2371::AID-CNCR28>3.0.CO;2-T, PubMed 8635109

Sundfør K, Trope CG, Kjørstad KE (1996)
Radical radiotherapy versus brachytherapy plus surgery in carcinoma of the cervix 2A and 2B--long-term results from a randomized study 1968-1980
Acta Oncol, 35 Suppl 8, 99-107
DOI 10.3109/02841869609098527, PubMed 9073055

Tropé C, Andersson H, Björkholm E, Frankendal B, Himmelman A, Högberg T, Horvath G, Petterson B, Persson H, Ryberg M, Simonsen E, Sorbe B, Stendahl U, Westholm B (1996)
Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group
Acta Oncol, 35 Suppl 8, 109-18
DOI 10.3109/02841869609098528, PubMed 9073056

Trope C, Hansen LJ, Kaern J, Abeler V (1996)
State of art in endometrial carcinoma
4TH CONGRESS OF THE EUROPEAN SOCIETY FOR GYNAECOLOGICAL ENDOSCOPY: THE UTERUS THROUGHOUT THE WOMAN'S LIFE, 107-115

Tropé C, Kaern J (1996)
Prognosis and management of borderline tumours of the ovary
Curr Opin Obstet Gynecol, 8 (1), 12-6
PubMed 8777251

Trope C, Sundfor K, Kristensen G, Iversen T (1996)
Surgical treatment for cervical cancer and presentation of the genito urinary function
XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1415-1424

Trope C, Sundfor K, Kristensen G, Iversen T (1996)
Standard and new approaches in surgery
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY - 21ST ESMO CONGRESS, EDUCATIONAL BOOK, 51-56

Publications 1995

Bjørge T, Gunbjørud AB, Haugen OA, Skare GB, Tropé C, Thoresen SO (1995)
Mass screening for cervical cancer in Norway: evaluation of the pilot project
Cancer Causes Control, 6 (6), 477-84
DOI 10.1007/BF00054154, PubMed 8580294

Kristensen GB, Baekelandt M, Vergote IB, Tropé C (1995)
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma
Eur J Cancer, 31A (11), 1778-80
DOI 10.1016/0959-8049(95)00274-m, PubMed 8541099

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Tropé CG, Pettersen EO (1995)
No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients
Gynecol Oncol, 57 (1), 79-85
DOI 10.1006/gyno.1995.1102, PubMed 7705705

Lyng H, Sundfør K, Tropé CG, Rofstad EK (1995)
Heterogeneity in pO2 and histological appearance in human cervix carcinoma.
In Tumor Oxygenation (Vaupel P, Kelleher DK, Günderoth M, eds.), Gustav Fischer Verlag, New York, 249-258
PublikaID 43

Makar AP, Baekelandt M, Tropé CG, Kristensen GB (1995)
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
Gynecol Oncol, 56 (2), 175-80
DOI 10.1006/gyno.1995.1027, PubMed 7896181

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1995)
The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma
Acta Oncol, 34 (6), 797-802
DOI 10.3109/02841869509127189, PubMed 7576748

Raju KS, King RJ, Kaern J, Sumner D, Abeler VM, Mandalaya S, Trope C (1995)
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer
Int J Gynecol Cancer, 5 (2), 94-100
DOI 10.1046/j.1525-1438.1995.05020094.x, PubMed 11578461

Scheistrøen M, Tropé C, Koern J, Pettersen EO, Abeler VM, Kristensen GB (1995)
Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients
Cancer, 75 (1), 72-80
DOI 10.1002/1097-0142(19950101)75:1<72::aid-cncr2820750113>3.0.co;2-g, PubMed 7804980

Tropé C, Kristensen G (1995)
[Preoperative identification of malignancy among women with a pelvic mass]
Tidsskr Nor Laegeforen, 115 (7), 812-3
PubMed 7701484

Publications 1994

Dørum A, Kristensen GB, Tropé C (1994)
A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma
Eur J Cancer, 30A (10), 1470-4
DOI 10.1016/0959-8049(94)00240-6, PubMed 7833104

Kaern J, Tropé CG, Kristensen GB, Pettersen EO (1994)
Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
Cancer, 73 (7), 1870-7
DOI 10.1002/1097-0142(19940401)73:7<1870::aid-cncr2820730716>3.0.co;2-3, PubMed 8137213

Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO (1994)
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
DOI 10.1016/s0002-9378(94)70215-2, PubMed 8116701

Kristiansen E, Jenkins A, Kristensen G, Ask E, Kaern J, Abeler V, Lindqvist BH, Tropé C, Kristiansen BE (1994)
Human papillomavirus infection in Norwegian women with cervical cancer
APMIS, 102 (2), 122-8
DOI 10.1111/j.1699-0463.1994.tb04856.x, PubMed 8167008

Makar AP, Holm R, Kristensen GB, Nesland JM, Tropé CG (1994)
The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
Int J Gynecol Cancer, 4 (3), 194-199
DOI 10.1046/j.1525-1438.1994.04030194.x, PubMed 11578406

Ramm K, de Flon S, Piene H, Trope C (1994)
Improving the quality of anti-emetic therapy
Int J Qual Health Care, 6 (1), 37-40
DOI 10.1093/intqhc/6.1.37, PubMed 7953202

Tropé C, Kaern J (1994)
DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor?
Gynecol Oncol, 53 (1), 1-4
DOI 10.1006/gyno.1994.1077, PubMed 8175006

TROPE C, SORBE B, SIMONSEN E, BERTELSEN K, JORGENSEN NP, SCHEISTROEN M, WESTBERG R (1994)
A PHASE-II, NONRANDOMIZED STUDY OF SINGLE-AGENT PACLITAXEL (TAXOL(R)) IN PATIENTS WITH PREVIOUSLY UNTREATED FIGO STAGE-III, SUBOPTIMALLY RESECTED OVARIAN-CANCER - A PRELIMINARY-REPORT
Int. J. Gynecol. Cancer, 4 1, 7-12

Publications 1993

Berek JS, Martínez-Maza O, Hamilton T, Tropé C, Kaern J, Baak J, Rustin GJ (1993)
Molecular and biological factors in the pathogenesis of ovarian cancer
Ann Oncol, 4 Suppl 4, 3-16
DOI 10.1093/annonc/4.suppl_4.s3, PubMed 8312207

Carl J, Tropé C (1993)
Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling
Int J Gynecol Cancer, 3 (5), 265-270
DOI 10.1046/j.1525-1438.1993.03050265.x, PubMed 11578356

Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL (1993)
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
DOI 10.1002/path.1711710207, PubMed 8283348

Horvath G, Baldetorp B, Fernö M, Johansson M, Nesland J, Tropé C (1993)
Effect of estradiol on tumor growth, cell kinetics and p53 oncoprotein expression in human endometrial adenocarcinoma heterotransplanted into nude mice
In Vivo, 7 (5), 451-6
PubMed 8110990

Kaern J, Tropé CG, Abeler VM (1993)
A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities
Cancer, 71 (5), 1810-20
DOI 10.1002/1097-0142(19930301)71:5<1810::aid-cncr2820710516>3.0.co;2-v, PubMed 8383580

Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO (1993)
DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary
Int J Gynecol Cancer, 3 (6), 349-358
DOI 10.1046/j.1525-1438.1993.03060349.x, PubMed 11578368

Lien HH, Blomlie V, Iversen T, Tropé C, Sundfør K, Abeler VM (1993)
Clinical stage I carcinoma of the cervix. Value of MR imaging in determining invasion into the parametrium
Acta Radiol, 34 (2), 130-2
PubMed 8452717

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG (1993)
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
DOI 10.1046/j.1525-1438.1993.03050299.x, PubMed 11578361

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Gynecol Oncol, 49 (1), 3-7
DOI 10.1006/gyno.1993.1076, PubMed 8482556

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Serum CA 125 level allows early identification of nonresponders during induction chemotherapy
Gynecol Oncol, 49 (1), 73-9
DOI 10.1006/gyno.1993.1089, PubMed 8482563

Makar AP, Kristensen GB, Nesland J, Børmer OP, Tropé CG (1993)
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies
Int J Gynecol Cancer, 3 (2), 116-121
DOI 10.1046/j.1525-1438.1993.03020116.x, PubMed 11578331

Nordal RN, Kjørstad KE, Stenwig AE, Tropé CG (1993)
Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985
Int J Gynecol Cancer, 3 (2), 110-115
DOI 10.1046/j.1525-1438.1993.03020110.x, PubMed 11578330

Reed W, Abeler VM, Tropé CG (1993)
[Villous glandular adenocarcinoma of the uterine cervix. A subtype with favourable prognosis?]
Tidsskr Nor Laegeforen, 113 (20), 2569-71
PubMed 8236177

Scheiströen M, Tropé C (1993)
Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva
Acta Oncol, 32 (6), 657-61
DOI 10.3109/02841869309092448, PubMed 7505091

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V (1993)
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors
Gynecol Oncol, 51 (2), 236-43
DOI 10.1006/gyno.1993.1279, PubMed 8276300

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Tropé CG (1993)
Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
Am J Obstet Gynecol, 169 (1), 40-52
DOI 10.1016/0002-9378(93)90129-7, PubMed 8333474

Vergote IB, Winderen M, De Vos LN, Tropé CG (1993)
Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy
Cancer, 71 (7), 2250-60
DOI 10.1002/1097-0142(19930401)71:7<2250::aid-cncr2820710715>3.0.co;2-#, PubMed 8453546

Willén R, Himmelmann A, Långström-Einarsson E, Fernö M, Ranstam J, Baldetorp B, Skjaerris J, Prien-Larsen J, Tropé C, Stendahl U (1993)
Prospective malignancy grading, flow cytometry DNA-measurements and adjuvant chemotherapy for invasive squamous cell carcinoma of the uterine cervix
Anticancer Res, 13 (4), 1187-96
PubMed 8352543

Publications 1992

Ask E, Jenkins A, Kaern J, Trope C, Kristiansen BE (1992)
Comparison of HPV detection in parallel biopsies and cervical scrapes by PCR
APMIS, 100 (8), 752-6
DOI 10.1111/j.1699-0463.1992.tb03995.x, PubMed 1325806

BERGSJO P, TROPE C, IVERSEN T (1992)
KOLSTAD,PER AUGUST 31, 1925 AUGUST 14, 1991 - OBITUARY
Acta Obstet. Gynecol. Scand., 71 (6), 494-495
DOI 10.3109/00016349209021105

Bye A, Kaasa S, Ose T, Sundfør K, Tropé C (1992)
The influence of low fat, low lactose diet on diarrhoea during pelvic radiotherapy
Clin Nutr, 11 (3), 147-53
DOI 10.1016/0261-5614(92)90075-2, PubMed 16839990

Børresen AL, Helland A, Nesland J, Holm R, Trope C, Kaern J (1992)
Papillomaviruses, p53, and cervical cancer
Lancet, 339 (8805), 1350-1
PubMed 1350005

Kaern J, Iversen T, Tropé C, Pettersen EO, Nesland JM (1992)
Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method
Int J Gynecol Cancer, 2 (4), 169-174
DOI 10.1046/j.1525-1438.1992.02040169.x, PubMed 11576255

Kaern J, Wetteland J, Tropé CG, Farrants GW, Juhng SW, Pettersen EO, Reith A, Danielsen HE (1992)
Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer
Cytometry, 13 (3), 314-21
DOI 10.1002/cyto.990130314, PubMed 1576895

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1992)
CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
Gynecol Oncol, 45 (3), 323-8
DOI 10.1016/0090-8258(92)90313-8, PubMed 1612511

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG (1992)
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296

Makar AP, Tropé CG (1992)
Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors
Acta Obstet Gynecol Scand, 71 (5), 331-6
DOI 10.3109/00016349209021068, PubMed 1355947

Makar AP, Tropé CG (1992)
Gynecologic malignancy and surgery: from quantity to quality of life
Curr Opin Obstet Gynecol, 4 (3), 419-29
PubMed 1623153

Onsrud M, Grahm I, Gaudernack G, Tropé C (1992)
Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix
Acta Obstet Gynecol Scand, 71 (2), 135-9
DOI 10.3109/00016349209007971, PubMed 1316042

Ramm K, Vergote IB, Kaern J, Tropé CG (1992)
Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look
Gynecol Oncol, 46 (2), 203-7
DOI 10.1016/0090-8258(92)90256-i, PubMed 1379961

TROPE C, IVERSEN T (1992)
KOLSTAD,PER (1925-1991) - IN MEMORIAM
Gynecol. Oncol., 46 (2), 141-142
DOI 10.1016/0090-8258(92)90244-D

Tropé C, Makar A (1992)
Unsettled questions regarding ovarian cancer
Acta Obstet Gynecol Scand Suppl, 155, 7-18
DOI 10.1111/j.1600-0412.1992.tb00002.x, PubMed 1502893

Tropé C, Makar A, Kaern J (1992)
DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review
Acta Obstet Gynecol Scand Suppl, 155, 95-7
DOI 10.1111/j.1600-0412.1992.tb00013.x, PubMed 1502897

Vergote I, Himmelmann A, Frankendal B, Scheistrøen M, Vlachos K, Tropé C (1992)
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
Gynecol Oncol, 47 (3), 282-6
DOI 10.1016/0090-8258(92)90127-5, PubMed 1473738

Vergote I, Larsen RH, de Vos L, Nesland JM, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K (1992)
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model
Gynecol Oncol, 47 (3), 366-72
DOI 10.1016/0090-8258(92)90141-5, PubMed 1473751

Vergote I, Larsen RH, De Vos L, Winderen M, Ellingsen T, Bjørgum J, Hoff P, Aas M, Tropé C, Nustad K (1992)
Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice
Gynecol Oncol, 47 (3), 358-65
DOI 10.1016/0090-8258(92)90140-e, PubMed 1473750

Vergote IB, Abeler VM, Børmer OP, Stigbrand T, Tropé C, Nustad K (1992)
CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma
Tumour Biol, 13 (3), 168-74
DOI 10.1159/000217761, PubMed 1626181

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjørstad KE, Tropé CG (1992)
Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer
Cancer, 69 (3), 741-9
DOI 10.1002/1097-0142(19920201)69:3<741::aid-cncr2820690322>3.0.co;2-g, PubMed 1730124

Publications 1991

Jenkins A, Kristiansen BE, Ask E, Oskarsen B, Kristiansen E, Lindqvist B, Trope C, Kjørstad K (1991)
Detection of genital papillomavirus types by polymerase chain reaction using common primers
APMIS, 99 (7), 667-73
DOI 10.1111/j.1699-0463.1991.tb01244.x, PubMed 1648934

Lien HH, Blomlie V, Tropé C, Kaern J, Abeler VM (1991)
Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium
AJR Am J Roentgenol, 157 (6), 1221-3
DOI 10.2214/ajr.157.6.1950869, PubMed 1950869

Sert MB, Kaern J, Trope C (1991)
The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis
Eur J Cancer, 27 (3), 302
DOI 10.1016/0277-5379(91)90531-h, PubMed 1827319

Tropé C, Kaern J, Pettersen EO, Iversen OE (1991)
[DNA examinations in gynecological cancer and breast cancer]
Tidsskr Nor Laegeforen, 111 (13), 1638-42
PubMed 2063365

Tropé C, Kaern J, Vergote I (1991)
Intraperitoneal antineoplastic agents in the management of ovarian cancer
Eur J Surg Suppl (561), 83-6
PubMed 1720054

Tropé CG, Makar AP (1991)
Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer
Curr Opin Oncol, 3 (5), 908-19
DOI 10.1097/00001622-199110000-00016, PubMed 1751582

Publications 1990

Horvath G, Johnsson JE, Tropé C, Samuelsson L, Alm P, Olsson H (1990)
Influence of "nuclear" estrogen receptor content on prognosis of early stage carcinoma of the uterine body. A short-time follow-up
Neoplasma, 37 (1), 43-6
PubMed 2320180

Horváth G, Tropé C, Almbo HE (1990)
A phase II study of toremifene in carcinoma corporis uteri. Preliminary communication
J Steroid Biochem, 36 (3), 241
DOI 10.1016/0022-4731(90)90017-m, PubMed 2142245

Kaern J, Tropé C, Abeler V, Iversen T, Kjørstad K (1990)
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer
Acta Oncol, 29 (1), 25-8
DOI 10.3109/02841869009089987, PubMed 2310600

Kaern J, Trope C, Kjorstad KE, Abeler V, Pettersen EO (1990)
Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary
Gynecol Oncol, 38 (3), 452-7
DOI 10.1016/0090-8258(90)90090-8, PubMed 2172121

Kaern J, Tropé C, Kjørstad KE, Nordal R, Sundfør K, Vergote I, Vossli S, Abeler V, Sandvei R (1990)
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]
Tidsskr Nor Laegeforen, 110 (21), 2759-62
PubMed 2219049

Nilsson T, Alm P, Malmström H, Simonsen E, Tropé C (1990)
A 16-year-old girl with invasive carcinoma of the vulva
Acta Obstet Gynecol Scand, 69 (6), 541-2
DOI 10.3109/00016349009013334, PubMed 2284904

Tropé C, Kaern J, Vergote I, Vossli S (1990)
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas
Cancer Chemother Pharmacol, 26 Suppl, S45-7
DOI 10.1007/BF00685418, PubMed 2347051

Vergote IB, Abeler VM, Kjørstad KE, Tropé C (1990)
Management of malignant ovarian immature teratoma. Role of adriamycin
Cancer, 66 (5), 882-6
DOI 10.1002/1097-0142(19900901)66:5<882::aid-cncr2820660512>3.0.co;2-8, PubMed 2201432

Publications 1989

Horvath G, Alm P, Trope C, Fernö M (1989)
Changes in tumor morphology in one human endometrial carcinosarcoma heterotransplanted into nude mice
In Vivo, 3 (2), 113-6
PubMed 2519836

Horvath G, Tropé C, Fernö M, Alm P (1989)
Estrogen receptor content in nuclear pellet from adenocarcinoma corporis uteri biopsies
Neoplasma, 36 (5), 611-4
PubMed 2812155

Lindahl B, Alm P, Fernö M, Killander D, Långström E, Norgren A, Tropé C (1989)
Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma
Acta Oncol, 28 (4), 595-9
DOI 10.3109/02841868909092278, PubMed 2789839

Malmström H, Simonsen E, Tropé C (1989)
Primary invasive squamous cell carcinoma of the vagina
Acta Obstet Gynecol Scand, 68 (5), 411-5
DOI 10.3109/00016348909021012, PubMed 2520784

Trope C, Lindahl B, Kaern J, Iversen OE (1989)
Usefulness of flow cytometric DNA measurements in genital and breast cancers
Eur J Gynaecol Oncol, 10 (3), 191-5
PubMed 2659366

Tveit KM, Kaern J, Hoifodt HK, Pettersen EO, Abeler V, Davy M, Hannisdal E, Trope C (1989)
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay
Anticancer Res, 9 (6), 1577-82
PubMed 2483300

Publications 1988

Horvath G, Tropé C, Alm P, Fernö M (1988)
Heterotransplantation of human malignant endometrial tumors into nude mice
In Vivo, 2 (6), 361-5
PubMed 2979858

Wahlberg P, Fex G, Biörklund A, Tropé C, Willén R (1988)
Quantitation and localization of cellular retinol-binding protein in squamous-cell carcinomas of the cervix uteri and of the oral cavity
Int J Cancer, 41 (5), 771-6
DOI 10.1002/ijc.2910410523, PubMed 3366495

Wennerberg J, Biörklund A, Tropé C (1988)
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck
Arch Otolaryngol Head Neck Surg, 114 (2), 162-7
DOI 10.1001/archotol.1988.01860140060022, PubMed 3337774

Wennerberg J, Willén R, Tropé C (1988)
Changes in histology and cell kinetics during the growth course of xenografted squamous cell carcinoma
Arch Otolaryngol Head Neck Surg, 114 (7), 781-7
DOI 10.1001/archotol.1988.01860190085030, PubMed 3382535

Publications 1987

Hauksson A, Bynke H, Tropé C (1987)
A serious ovarian cystadenocarcinoma metastatic to both eyes
Acta Obstet Gynecol Scand, 66 (2), 187-8
DOI 10.3109/00016348709083048, PubMed 3618146

Horvath G, Fernö M, Tropé C (1987)
Comparison of estrogen receptor enzyme immunoassay and a radioligand binding assay (isoelectric focusing) in adenocarcinoma of the uterine body
Neoplasma, 34 (3), 313-7
PubMed 3614465

Johnsson JE, Möller T, Ranstam J, Jarlman O, Samuelsson L, Trope C (1987)
Prevalence of mammary carcinoma in patients with gynaecologic cancer
Ann Chir Gynaecol, 76 (2), 88-92
PubMed 3497605

Lindahl B, Alm P, Fernö M, Killander D, Långström E, Norgren A, Trope C (1987)
Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation
Anticancer Res, 7 (4B), 791-7
PubMed 3674764

Lindahl B, Alm P, Killander D, Långström E, Tropé C (1987)
Flow cytometric DNA analysis of normal and cancerous human endometrium and cytological-histopathological correlations
Anticancer Res, 7 (4B), 781-9
PubMed 3674763

Tropé C (1987)
Melphalan with and without doxorubicin in advanced ovarian cancer
Obstet Gynecol, 70 (4), 582-6
PubMed 3306509

Wahlberg P, Wennerberg J, Alm P, Biörklund A, Tropé C (1987)
The effect of continuous bleomycin infusion on the growth and cell kinetics of heterotransplanted squamous cell carcinoma of the head and neck
Anticancer Res, 7 (1), 55-8
PubMed 2436565

Willén R, Tropé C, Långström E, Ranstam J, Killander D, Clase L (1987)
Prospective malignancy grading and flow cytometry DNA distribution in biopsy specimens from invasive squamous cell carcinoma of the uterine cervix
Anticancer Res, 7 (2), 235-42
PubMed 3592637

Publications 1986

Andreasson L, Biörklund A, Mercke C, Scheike O, Andersson T, Brismar J, Elner A, Hellekant C, Landberg T, Tropé C (1986)
Intra-arterial mitomycin C and intravenous bleomycin as induction chemotherapy in advanced head and neck cancer--a phase II study
Radiother Oncol, 7 (1), 37-45
DOI 10.1016/s0167-8140(86)80123-2, PubMed 2430316

Lindahl B, Alm P, Fernö M, Grundsell H, Norgren A, Tropé C (1986)
Relapse of endometrial carcinoma related to steroid receptor concentration, staging, histologic grading and myometrial invasion
Anticancer Res, 6 (6), 1317-20
PubMed 3813487

Tropé C, Horvath G, Haadem K, Gudmundsson T, Simonsen E (1986)
Doxorubicin-cisplatin combination chemotherapy for recurrent carcinoma of the cervix
Cancer Treat Rep, 70 (11), 1325-6
PubMed 3768874

Wennerberg J, Willén R, Biörklund A, Tropé C (1986)
Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice
Anticancer Res, 6 (5), 1165-70
PubMed 3800324

Publications 1985

Simonsen E, Johnsson JE, Tropé C, Alm P (1985)
Basal cell carcinoma of the vulva
Acta Obstet Gynecol Scand, 64 (3), 231-4
DOI 10.3109/00016348509155118, PubMed 4013687

Simonsen EF, Johnsson JE, Tropé C (1985)
[CO2 laser in surgical treatment of vulvar and vaginal cancer]
Ugeskr Laeger, 147 (48), 3889-92
PubMed 3936249

Thorvinger B, Jörgensen CW, Samuelsson L, Tropé C (1985)
Transcatheter intraarterial management of gynecologic tumors
Acta Radiol Diagn (Stockh), 26 (6), 701-4
DOI 10.1177/028418518502600611, PubMed 2417454

Tropé C, Danneskiold-Samsøe P, Hauksson A (1985)
High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study
Neoplasma, 32 (4), 507-12
PubMed 4047261

Willén H, Eklund G, Johnsson JE, Stendahl U, Tropé C (1985)
Invasive squamous cell carcinoma of the uterine cervix. VIII. Survival and malignancy grading in patients treated by irradiation in Lund 1969-1970
Acta Radiol Oncol, 24 (1), 41-50
DOI 10.3109/02841868509134363, PubMed 2984901

Willén H, Willén R, Tropé C (1985)
[A new prognostic instrument. Histopathological multi-factor analysis of invasive squamous cell carcinoma of the cervix uteri]
Lakartidningen, 82 (6), 394-7
PubMed 3982163

Publications 1984

Lindahl B, Alm P, Fernö M, Norgren A, Tropé C (1984)
Plasma steroid hormones, cytosol receptors, and thymidine incorporation rate in endometrial carcinoma
Am J Obstet Gynecol, 149 (6), 607-12
DOI 10.1016/0002-9378(84)90243-6, PubMed 6742042

Sigurdsson K, Alm P, Gullberg B, Johnsson JE, Tropé C (1984)
[Staging and differentiated grading are the factors influencing mortality in ovarian cancer]
Lakartidningen, 81 (23), 2354-7
PubMed 6738240

Simonsen E, Johnsson JE, Tropé C (1984)
Radical vulvectomy with warm-knife and open-wound techniques in vulvar malignancies
Gynecol Oncol, 17 (1), 22-31
DOI 10.1016/0090-8258(84)90056-8, PubMed 6693050

Simonsen E, Johnsson JE, Tropé C, Alm P, Ranstam J (1984)
Stage I squamous cell carcinoma of the vulva
Acta Radiol Oncol, 23 (6), 443-8
DOI 10.3109/02841868409136046, PubMed 6099037

Simonsen E, Nordberg UB, Johnsson JE, Lamm IL, Tropé C (1984)
Radiation therapy and surgery in the treatment of regional lymph nodes in squamous cell carcinoma of the vulva
Acta Radiol Oncol, 23 (6), 433-42
DOI 10.3109/02841868409136045, PubMed 6099036

Thorvinger B, Hauksson A, Samuelsson L, Tropé C (1984)
Computed tomography in advanced carcinoma of the uterine cervix
Acta Radiol Diagn (Stockh), 25 (5), 423-6
DOI 10.1177/028418518402500514, PubMed 6507136

Tropé C, Johnsson JE, Simonsen E, Christiansen H, Cavallin-Ståhl E, Horváth G (1984)
Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin
Am J Obstet Gynecol, 149 (4), 379-81
DOI 10.1016/0002-9378(84)90147-9, PubMed 6539567

Wennerberg J, Alm P, Biörklund A, Killander D, Långström E, Tropé C (1984)
Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment
Int J Cancer, 33 (2), 213-22
DOI 10.1002/ijc.2910330209, PubMed 6420350

Wennerberg J, Alm P, Lögdberg L, Tropé C (1984)
Beta 2-microglobulin in squamous cell carcinomas of the head and neck and in tumours heterotransplanted into nude athymic mice
Acta Otolaryngol, 98 (3-4), 335-42
DOI 10.3109/00016488409107571, PubMed 6388230

Publications 1983

Gynning I, Johnsson JE, Alm P, Tropé C (1983)
Age and prognosis in stage Ib squamous cell carcinoma of the uterine cervix
Gynecol Oncol, 15 (1), 18-26
DOI 10.1016/0090-8258(83)90112-9, PubMed 6822365

Sigurdsson K, Johnsson JE, Tropé C (1983)
Tranexamic acid for the treatment of advanced ovarian carcinoma
Acta Obstet Gynecol Scand, 62 (3), 265-6
DOI 10.3109/00016348309155805, PubMed 6312728

Simonsen E, Johnsson JE, Tropé C (1983)
CO2 laser for the treatment of invasive vulvar and vaginal cancer
Neoplasma, 30 (3), 359-64
PubMed 6408494

Tropé C, Johnsson JE, Simonsen E, Sigurdsson K, Stendahl U, Mattsson W, Gullberg B (1983)
Bleomycin-mitomycin C in advanced carcinoma of the cervix. A third look
Cancer, 51 (4), 591-3
DOI 10.1002/1097-0142(19830215)51:4<591::aid-cncr2820510406>3.0.co;2-9, PubMed 6185206

Wennerberg J, Tropé C, Biörklund A (1983)
Heterotransplantation of human head and neck tumours into nude mice
Acta Otolaryngol, 95 (1-2), 183-90
DOI 10.3109/00016488309130933, PubMed 6829300

Publications 1982

Lindahl B, Alm P, Borg A, Fernö M, Grundsell H, Johnsson JE, Norgren A, Tropé C (1982)
Correlation between estradiol-17 beta and progesterone cytosol receptor concentration, histologic differentiation and 3H-thymidine incorporation in endometrial carcinoma
Anticancer Res, 2 (4), 203-7
PubMed 7149649

Sigurdsson K, Johnsson JE, Tropé C (1982)
Carcinoma of the ovary in stage III. Effects of postoperative chemotherapy, radiation therapy and repeat laparotomy
Acta Radiol Oncol, 21 (3), 181-9
DOI 10.3109/02841868209134003, PubMed 6293259

Sigurdsson K, Johnsson JE, Tropé C (1982)
Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy
Ann Chir Gynaecol, 71 (6), 321-9
PubMed 6297368

Simonsen E, Alm P, Johnsson JE, Tropé C (1982)
The recovery pattern of patients with vulvar melanoma treated by combined surgery and radiation therapy
Ann Chir Gynaecol, 71 (6), 334-9
PubMed 7159003

Tropé C, Grundsell H, Henrikson H, Johnsson JE, Lindahl B, Simonsson E (1982)
Giant condyloma acuminatum with focal malignant degeneration
Acta Obstet Gynecol Scand, 61 (1), 93-5
DOI 10.3109/00016348209156960, PubMed 7090755

Tropé C, Johnsson JE, Sigurdsson K, Simonsen E (1982)
High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma
Cancer Treat Rep, 66 (6), 1441-3
PubMed 6177415

Tropé C, Sigurdsson K (1982)
Use of tissue culture in predictive testing of drug sensitivity in human ovarian cancer. Correlation between in vitro results and the response in vivo
Neoplasma, 29 (3), 309-14
PubMed 7133226

Tropé C, Simonsen E, Johnsson JE, Sigurdsson K (1982)
[Bleomycin combined with mitomycin C in recurrent cervix cancer]
Lakartidningen, 79 (17), 1689-91
PubMed 6178913

Tropé C, Thiséus S, Jacobsson S, Palmer B, Johnsson JE (1982)
[Tissue damage after extravasal deposition of doxorubicin]
Lakartidningen, 79 (17), 1686-8
PubMed 7098661

Tropé C, Wennerberg J, Alm P, von Eyben FE (1982)
Heterotransplantation of two human tumours in athymic mice and asplenic-athymic mice
Acta Pathol Microbiol Immunol Scand A, 90 (1), 75-7
DOI 10.1111/j.1699-0463.1982.tb00065_90a.x, PubMed 7080816

Tropé C, Wennerberg J, Johansson S, Unsgård B (1982)
Metastasis of a cultured human bladder carcinoma cell line transplanted into nude athymic mice
Neoplasma, 29 (4), 421-6
PubMed 7133234

von Eyben FE, Skude G, Tropé C, Wennerberg J, Mikulowski P (1982)
Lactate dehydrogenase isoenzyme 1 (LDH-1) in athymic mice with xenografts of a human testicular germ cell tumor
Mol Gen Genet, 186 (3), 427-31
DOI 10.1007/BF00729464, PubMed 6289049

Von Eyben FE, Tropé C, Ljungberg O, Alm P, Wennerberg J, Gulberg B (1982)
Histologic pattern and growth in two human testis cancers before and after transplantation to nude mice
Cancer, 50 (12), 2845-53
DOI 10.1002/1097-0142(19821215)50:12<2845::aid-cncr2820501226>3.0.co;2-7, PubMed 7139575

Publications 1981

Grundsell H, Ekman G, Gullberg B, Johnsson JE, Larsson G, Lindahl B, Möller T, Tropé C (1981)
Some aspects of prophylactic oophorectomy and ovarian carcinoma
Ann Chir Gynaecol, 70 (1), 36-42
PubMed 7259058

Tropé C (1981)
The preoperative diagnosis of malignancy of ovarian cysts
Neoplasma, 28 (1), 117-21
PubMed 7279055

Tropé C, Johnsson JE, Alm P, Landberg T, Olsson H, Wennerberg J (1981)
Human malignant melanoma heterotransplanted to nude mice
Neoplasma, 28 (5), 585-91
PubMed 7312076

Tropé C, Mattsson W, Gynning I, Johnsson JE, Sigurdsson K, Orbert B (1981)
Phase II study of spirogermanium in advanced ovarian malignancy
Cancer Treat Rep, 65 (1-2), 119-20
PubMed 6261944

Publications 1980

Astedt B, Tropé C (1980)
Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis
Experientia, 36 (6), 679-80
DOI 10.1007/BF01970136, PubMed 7418830

Biörklund A, Håkansson L, Stenstam B, Tropé C, Akerman M (1980)
On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study
Eur J Cancer (1965), 16 (5), 647-54
DOI 10.1016/0014-2964(80)90205-4, PubMed 7389791

Grundsell H, Henrikson H, Johnsson JE, Laurin J, Tropé C (1980)
Histological grading and treatment failures in carcinoma of the uterine body
Ann Chir Gynaecol, 69 (2), 65-9
PubMed 7377736

Grundsell H, Johnsson JE, Mattsson W, Tropé C (1980)
[Treatment of recurrent cervical cancer with doxorubicin in combination with methotrexate]
Lakartidningen, 77 (40), 3491-4
PubMed 7453347

Grundsell H, Johnsson JE, Tropé C (1980)
[A phase II study of prednimustine in advanced ovarian cancer]
Lakartidningen, 77 (39), 3394-7
PubMed 6161283

Svedman P, Tropé C (1980)
Colour test indicating potential infusate leakage sites in vein walls
Cancer Chemother Pharmacol, 5 (1), 71-2
DOI 10.1007/BF00578566, PubMed 6161716

Tropé C, Grundsell H, Johnsson JE, Cavallin-Ståhl E (1980)
A phase II study of Cis-platinum for recurrent corpus cancer
Eur J Cancer (1965), 16 (8), 1025-6
DOI 10.1016/0014-2964(80)90248-0, PubMed 7192215

Tropé C, Johnsson JE, Grundsell H, Mattsson W (1980)
Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: a third look
Obstet Gynecol, 55 (4), 488-92
PubMed 7366905

Tropé C, Johnsson JE, Larsson G, Simonsen E (1980)
Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva
Cancer Treat Rep, 64 (4-5), 639-42
PubMed 6159078

Trope CG, Lögdberg L, Johnsson JE (1980)
beta 2-Microglobulin: a tumor marker of gynecologic cancer
Am J Obstet Gynecol, 137 (6), 743-4
DOI 10.1016/s0002-9378(15)33255-5, PubMed 6156602

Publications 1979

Grundsell H, Henriksson H, Johnsson JE, Tropé C (1979)
Prognosis of adenocarcinoma of the uterine cervix
Gynecol Oncol, 8 (2), 204-8
DOI 10.1016/0090-8258(79)90027-1, PubMed 115756

Grundsell H, Johnsson JE, Lindberg LG, Ström H, Tekavec E, Tropé C, Bekassy Z (1979)
Vaginal smear history in patients with invasive cervical carcinoma
Ann Chir Gynaecol, 68 (4), 127-9
PubMed 533219

Johnsson JE, Tropé C, Mattsson W, Grundsell H, Aspegren K, Könyves I (1979)
Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma
Cancer Treat Rep, 63 (3), 421-4
PubMed 371798

Tropé C, Aspegren K, Kullander S, Astedt B (1979)
Heterogeneous response of disseminated human ovarian cancers to cytostatics in vitro
Acta Obstet Gynecol Scand, 58 (6), 543-6
DOI 10.3109/00016347909154616, PubMed 550694

Publications 1978

Kullander S, Rausing A, Tropé C (1978)
Human ovarian tumours heterotransplanted to "nude" mice
Acta Obstet Gynecol Scand, 57 (2), 149-59
DOI 10.3109/00016347809155895, PubMed 636856

Tropé C, Selvik G, Kullander S, Mattsson W, Mühlow A, Astedt B (1978)
Antineoplastic-drug effect evaluated with a new X-ray stereophotographic measurement of the tumour volume
Ann Chir Gynaecol, 67 (2), 82-4
PubMed 354467

Publications 1977

Aspegren K, Eriksson S, Liedberg G, Tropé C (1977)
In vitro responsiveness of human gastric carcinoma to pentagastrin
Scand J Gastroenterol, 12 (2), 253-6
PubMed 847394

Aspegren K, Tropé C (1977)
In vitro effects of prolactin and hydrocortisone on 7,12-DMBA-induced mammary tumour and virus-induced sarcoma in the rat
Acta Pathol Microbiol Scand A, 85A (1), 57-62
DOI 10.1111/j.1699-0463.1977.tb03868.x, PubMed 402063

Astedt B, Glifberg I, Mattsson W, Tropé C (1977)
Arrest of growth of ovarian tumor by tranexamic acid
JAMA, 238 (2), 154-5
DOI 10.1001/jama.238.2.154, PubMed 577288

Astedt B, Mattsson W, Tropé C (1977)
Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis
Acta Med Scand, 201 (5), 491-3
DOI 10.1111/j.0954-6820.1977.tb15735.x, PubMed 899870

Mattsson W, Gynning I, Tropé C, Astedt B (1977)
Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen
Acta Radiol Ther Phys Biol, 16 (2), 97-108
DOI 10.3109/02841867709134300, PubMed 301341

Tropé C, Mattsson W, Astedt B (1977)
A phase II study of combined adriamycin, L-PAM, and methotrexate with citrovorum factor rescue in advanced ovarian carcinomas
Tumori, 63 (5), 469-77
DOI 10.1177/030089167706300508, PubMed 304624

Publications 1976

Aspegren K, Biörklund A, Tropé C (1976)
Heterogeneity in in vitro response to progesterone and melphalan of mammary tumours induced in the rat by 7,12-DMBA
Acta Pathol Microbiol Scand A, 84 (4), 297-300
DOI 10.1111/j.1699-0463.1976.tb00117.x, PubMed 822690

Axelsson JA, Källén B, Nilsson O, Tropé C (1976)
Effect of 2-mercaptoethanol on the mixed leukocyte reaction in man. Probable effect on blastogenic factor stabilization
Acta Pathol Microbiol Scand C, 84C (5), 390-6
DOI 10.1111/j.1699-0463.1976.tb00046.x, PubMed 136863

Publications 1975

Tropé C (1975)
Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis carcinoma
Neoplasma, 22 (2), 171-80
PubMed 1161112

Tropé C, Håkansson L, Dencker H (1975)
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs
Neoplasma, 22 (4), 423-9
PubMed 1196425

Publications 1974

Håkansson L, Tropé C (1974)
On the presence within tumours of clones that differ in sensitivity to cytostatic drugs
Acta Pathol Microbiol Scand A, 82 (1), 35-40
DOI 10.1111/j.1699-0463.1974.tb03825.x, PubMed 4827349

Håkansson L, Tropé C (1974)
Cell clones with different sensitivity to cytostatic drugs in methylcholanthrene-induced mouse sarcomas
Acta Pathol Microbiol Scand A, 82 (1), 41-7
DOI 10.1111/j.1699-0463.1974.tb03826.x, PubMed 4827350

Tropé C (1974)
Selective elimination in vitro of sensitive cell clones in methylcholanthrene induced sarcoma by vinblastine sulphate
Acta Pathol Microbiol Scand A, 82 (3), 419-26
DOI 10.1111/j.1699-0463.1974.tb00367.x, PubMed 4854220

Trope C (1974)
An in vitro study of the effect of cytostatic drugs on the DNA synthesis in experimental tumours: selection of cell clones during growth, transplantation, and metastasis
Lund, 39 s.
BIBSYS 950481637

Tropé C, Håkansson L (1974)
An in vitro study of cytostatic drug effect on the drug effect on the DNA synthesis in methylcholanthrene induced mouse sarcomas. Correlation between in vitro results and the response in vivo
Acta Pathol Microbiol Scand A, 82 (2), 189-98
DOI 10.1111/j.1699-0463.1974.tb03843.x, PubMed 4829059

Publications 1973

Håkansson L, Tropé C (1973)
An in vitro study of the effect of cytostatic drugs on DNA synthesis in methylcholanthrene induced mouse sarcomas and in rat Walker 256 tumours
Acta Pathol Microbiol Scand A, 81 (4), 552-8
DOI 10.1111/j.1699-0463.1973.tb00501.x, PubMed 4779705

Publications 1951

TROPE CG, CARLSON D (1951)
[A year's experience in an abortion consultation clinic connected with the Landskrona child care center]
Sven Lakartidn, 48 (15), 885-94
PubMed 14846022